Who RFZO covers
A wearable sensor continuously measures glucose and sends readings to an app or dedicated reader. Under rules in force since June 9, 2026, it may be provided to patients continuing a previously granted entitlement after 18; adults newly diagnosed with type 1 diabetes who take four or more insulin doses a day; and patients on that therapy before conception, during pregnancy and for one year after childbirth.
How to obtain a sensor
For an adult or pregnant patient, initial approval requires an assessment from an endocrinologist at a tertiary-care institution, a medical-commission decision and RFZO branch certification. For a child, the assessment comes from a paediatric endocrinologist at the designated institution. Renewals also require medical review and RFZO confirmation.
What Danas and RTS reported
On July 29, Danas, citing RTS and commission head Jelica Bjekić Macut, reported broader access and sensor alarms for dangerous night-time hypoglycaemia. The account used the narrower phrases “diagnosed at 19” and “one year before pregnancy”; the official list instead covers a new diagnosis after 18 and the period before conception, during pregnancy and for one year after childbirth.
What to check before applying
If you are in one of the listed groups, ask an endocrinologist whether the medical indications are documented, which records the medical commission requires and which RFZO branch should receive them. Belonging to an age- or pregnancy-related category does not by itself guarantee approval.